أفضل بودكاسات DrugPatentWatch (2024)

1
Underutilized Opportunities: Exploring Patent Term Extensions for Medical Devices

19h ago

—

In a recent study published in the Expert Review of Medical Devices, researchers investigated the utilization of patent term extensions (PTEs) to extend regulatory timeframes for medical devices in the…Sourceبقلم DrugPatentWatch

1
Innovative Strategies in Drug Repurposing

30d ago

—

Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate drug development and reduce costs. This book chapter provides a…Sourceبقلم DrugPatentWatch

1
AI-Driven Drug Discovery: Transforming the Landscape of Pharmaceutical Research

2M ago

—

The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent study published in the Future Journal of Pharmaceutical Sciences evaluates…Sourceبقلم DrugPatentWatch

1
Innovative Financing Models for Repurposing Generic Drugs

1M ago

—

A paper presented at the 2nd International Conference on Systems Medicine, AI, and Drug Repurposing proposes a novel approach to overcoming the financial barriers associated with repurposing generic drugs through…Sourceبقلم DrugPatentWatch

1
Biosimilar Competition Does Not Reduce Patient Out-of-Pocket Costs for Biologic Drugs

2M ago

—

A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,…Sourceبقلم DrugPatentWatch

1
Unleashing Innovation: The Case for Permissionless R&D in Pharma

2M ago

—

A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the freedom to explore new technologies or businesses without needing prior…Sourceبقلم DrugPatentWatch

1
LACTOSE-Free Medicines: Which Drugs Contain LACTOSE?

3M ago

—

LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This guide is designed to provide information for healthcare providers to…Sourceبقلم DrugPatentWatch

1
GELATIN-Free Medicines: Which Drugs Contain GELATIN?

3M ago

—

GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This guide is designed to provide information for healthcare providers to…Sourceبقلم DrugPatentWatch

1
Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma

3M ago

—

Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic…Sourceبقلم DrugPatentWatch

1
Drug Excipient Business Development Reports now Available on Amazon

4M ago

—

Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable…Sourceبقلم DrugPatentWatch

1
Revolutionizing Patent Landscaping: A Human-Supervised AI Approach to Identify Tech Clusters

4M ago

—

The recent paper published in PLOS ONE presents a novel approach for efficiently retrieving a substantial number of patents related to specific technologies. The authors enhance an automated patent landscaping…Sourceبقلم DrugPatentWatch

1
Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book

5M ago

—

A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The…Sourceبقلم DrugPatentWatch

1
An AI Approach to Generate Novel Pharmaceuticals using Patent Data

5M ago

—

A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures…Sourceبقلم DrugPatentWatch

1
NPR on how low Drug Prices can Shortages

5M ago

—

A recent story by NPR echoes the findings of a collaboration between DrugPatentWatch and Bloomberg, which examined increasing competition between generic drug makers. The NPR article discusses the challenges in…Sourceبقلم DrugPatentWatch

1
Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals

5M ago

—

The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the…Sourceبقلم DrugPatentWatch

1
Decoding Pfizer’s Portfolio: A New Model for Precision in Pharma Investments

6M ago

—

In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation…Sourceبقلم DrugPatentWatch

1
Navigating Legal Waters: Study Delves into Inequitable Conduct in Drug Patent Cases

7M ago

—

Researchers from West Virginia University College of Law have conducted a study examining the frequency of drug patent invalidations based on inequitable conduct. The findings, published in JAMA, shed light…Sourceبقلم DrugPatentWatch

1
AI-Driven Strategies: Pharma’s Answer to Patent Expirations

7M ago

—

In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending…Sourceبقلم DrugPatentWatch

1
Maximizing Intellectual Property Value in the Biomedical Sector: A Case Study on Rucaparib Patents

7M ago

—

A paper titled “Analysis of Strategy for Extending Patent Protection of Rucaparib” by Zhifeng Wang. discusses the strategies employed by pharmaceutical companies to extend the patent protection period of the…Sourceبقلم DrugPatentWatch

1
Advancements in In Silico ADMET Modeling: A 20-Year Journey of Machine Learning in Drug Discovery at Bayer Pharma

7M ago

—

Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical…Sourceبقلم DrugPatentWatch

1
List of research papers citing DrugPatentWatch

8M ago

—

DrugPatentWatch has published a list of research papers citing DrugPatentWatch at https://www.drugpatentwatch.com/citations/ DrugPatentWatch.com is your key to unlocking the world of pharmaceutical research. These primary literature citations can benefit researchers,…Sourceبقلم DrugPatentWatch

1
Influencers of Generic Drug Utilization

8M ago

—

In a systematic review titled “Influencers of Generic Drug Utilization,” researchers aimed to shed light on the key factors influencing the use of generic prescription drugs in the United States.…Sourceبقلم DrugPatentWatch

1
Reviving an R&D Pipeline

8M ago

—

The article titled “Reviving an R&D Pipeline: A Step Change in the Phase II Success Rate” discusses Pfizer’s efforts to improve its research and development (R&D) productivity. The pharmaceutical industry…Sourceبقلم DrugPatentWatch

1
Factors that May Predict the Likelihood of Generic Drug Marketing Applications

8M ago

—

The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications. The study focused on abbreviated new drug applications (ANDAs) submitted to the…Sourceبقلم DrugPatentWatch

1
Measuring Patent Value Indicators

9M ago

—

“Measuring Patent Value Indicators with Patent Renewal Information” aims to address the research gap by constructing a dynamic model that incorporates both ex ante and ex post patent value indicators.…Sourceبقلم DrugPatentWatch

1
Maximizing Drug Patents’ Value: Strategies for Biomedical Companies

9M ago

—

The article “Maximizing the Value of Drug Patents Before Losing Exclusivity” discusses strategies for biomedical companies to maximize the value of their drug patents before the exclusivity period expires. In…Sourceبقلم DrugPatentWatch

1
From Expert AI to Snackable AI: A New Era in Pharma, as Seen by Sanofi’s CEO

9M ago

—

In a recent STAT article Sanofi CEO Paul Hudson discusses the potential of artificial intelligence (AI) in the pharmaceutical industry. While some in the industry have been hesitant to embrace…Sourceبقلم DrugPatentWatch

1
Understanding Patent Term Extensions: An Overview

9M ago

—

In the world of patents, the right to exclude others from using or selling an invention is granted only during the patent’s validity. Once a patent expires, this exclusivity vanishes.…Sourceبقلم DrugPatentWatch

1
Pharmacists Can Play Key Role in Drug Repurposing

9M ago

—

Pharmacists play a crucial role in drug repurposing due to the vast amount of opportunities that exist in this innovative approach. Drug development and registration can be costly, time-consuming, and…Sourceبقلم DrugPatentWatch

1
Key Factors for Choosing the Right CDMO

9M ago

—

In a guest column Kevin Wall, principal consultant and owner of Cincero Consulting, emphasizes the critical importance of selecting the right Contract Development and Manufacturing Organization (CDMO) for drug product…Sourceبقلم DrugPatentWatch

1
Strategies to Maximize Product Value Amid Loss of Exclusivity in the Pharmaceutical Industry

10M ago

—

Loss of exclusivity (LOE) doesn’t have to spell doom for branded drug revenue streams. In the face of impending patent expirations, pharmaceutical companies can adopt key approaches to preserve meaningful…Sourceبقلم DrugPatentWatch

1
Unsuccessful Regulatory Filings for Biosimilar Approval: A Comprehensive Review

10M ago

—

A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs. Over the past three decades, biotherapeutics have revolutionized healthcare by providing effective treatments for complex diseases…Sourceبقلم DrugPatentWatch

1
Drug Patent Reports now available on Amazon

10M ago

—

DrugPatentWatch now offers single drug reports for purchase on Amazon. These reports provide valuable insights and information about specific drugs. This convenient availability on Amazon allows users to easily access…Sourceبقلم DrugPatentWatch

1
Artificial Intelligence and Machine Learning in Drug Discovery and Development

10M ago

—

A recent paper published in the journal “Intelligent Medicine” article discusses various aspects of using AI and machine learning in the pharmaceutical industry for drug discovery and development. Results The…Sourceبقلم DrugPatentWatch

1
Prevalence and timing of authorized generics in the US market

10M ago

—

A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs that are marketed without their original branding. The article sheds…Sourceبقلم DrugPatentWatch

1
Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends

10M ago

—

A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings involving Orange Book and biologic patents, based…Sourceبقلم DrugPatentWatch

1
The Evolution of Reverse Payment Cases: Courts and Agencies’ Approaches in Pharma Litigation

10M ago

—

In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status of reverse payment cases against pharmaceutical companies. Reverse payment cases…Sourceبقلم DrugPatentWatch

1
Understanding the Impact of Authorized Generics on Drug Pricing: The Entacapone Case Study

10M ago

—

In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of generic competition. One such strategy is the use of “authorized…Sourceبقلم DrugPatentWatch

1
Review of 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020: A Focus on Intellectual Property and Regulatory Considerations

10M ago

—

A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as approved by the USFDA from 2010 to 2020. The study…Sourceبقلم DrugPatentWatch

1
DrugPatentWatch reveals NIH funding for patents

11M ago

—

Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity of Drugs Approved 2010–2019 and the Public Interest Protections of…Sourceبقلم DrugPatentWatch

1
Filing Strategies for Maximizing Pharma Patents

11M ago

—

In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,” Alexander R. Trimble, PhD, a prominent patent attorney, explores the…Sourceبقلم DrugPatentWatch

1
DrugChatter Featured Questions

12M ago

—

DrugChatter recently launched as an experimental AI chat-based business intelligence tool. Here’s some of the more interesting questions it’s been asked: Cost savings for bulk lipitor Who Invented Advil? What…Sourceبقلم DrugPatentWatch

1
DrugChatter.com: AI Chat for Biopharmaceutical Drug Insights

1y ago

—

Introducing DrugChatter.com: Empowering Access to Biopharmaceutical Drug Insights through AI Chat We are pleased to introduce DrugChatter.com, a groundbreaking platform that redefines the way professionals obtain concise, cited information on…Sourceبقلم DrugPatentWatch

1
NPR and DrugPatentWatch – Can drug injector pens be swapped?

1y ago

—

On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which could then be swapped to fix drug shortages. Referring to…Sourceبقلم DrugPatentWatch

1
Utilizing 505(b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges

1y ago

—

This article was originally published by Jiayi Chen, Zhifeng Zhao, Xinyu Wang and Jingjun Huang in Drug Repurposing – Advances, Scopes and Opportunities in Drug Discovery and is republished here…Sourceبقلم DrugPatentWatch

1
Social Return on Investment

1+ y ago

—

This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit, and government companies are quite good at calculating the costs…Sourceبقلم DrugPatentWatch

1
CDCDB: A large and continuously updated drug combination database

2y ago

—

This article was originally published by Guy Shtar, Louise Azulay, Omer Nizri, Lior Rokach & Bracha Shapira in Scientific Data volume 9, Article number: 263 under a Creative Commons Attribution…Sourceبقلم DrugPatentWatch

1
DrugPatentWatch named “Best of the Web” by Genetic Engineering News

2y ago

—

DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile highlighted the “new training modules designed to help you find…Sourceبقلم DrugPatentWatch

1
The value of method of use patent claims in protecting your therapeutic assets

2y ago

—

This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…Sourceبقلم DrugPatentWatch

1
DrugPatentWatch Week in Review

2y ago

—

FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…Sourceبقلم DrugPatentWatch

المدونة الصوتية تستحق الاستماع

DrugPatentWatch بودكاست

المدونة الصوتية تستحق الاستماع

دليل مرجعي سريع